USFDA lifts clinical hold on Phase 3 investigational new drug application for MaaT013
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.
Alpenglow has created an end-to-end 3D spatial biology solution including patented high-throughput 3D imaging
The combination will support clients in getting their end-to-end discovery and development programs delivered.
Apremilast Tablets, 10 mg, 20 mg, and 30 mg is a generic equivalent of reference listed drug (RLD) OTEZLA of Celgene.
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
The disease is caused by a mutation in the gene encoding HMG CoA reductase, inhibiting the enzyme’s activity.
China is among the top countries reporting a high number of diagnosed prevalent cases for gastric, breast, and bladder cancers among the 16 major markets
This expansion follows the groundbreaking of a large-scale commercial drug product facility in Stein (CH), in another milestone for Lonza’s Drug Product Services (DPS) offering
Subscribe To Our Newsletter & Stay Updated